Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Pathios Therapeutics Limited has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 distinct examiners and 3 distinct art units. STOCKTON, LAURA LYNNE is the busiest examiner, with 1 pending action.
The portfolio shows separate examination paths for each pending action. Counsel should coordinate claim terminology and scientific support across the applications, but tailor arguments to the individual examiner and art-unit record. The STOCKTON assignment is one active matter and does not indicate broader examiner concentration.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOCKTON, LAURA LYNNE | 1 | 75.3% | +33.7% |
| KENYON, JOHN S | 1 | 79.7% | +18.2% |
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18849834 | 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | STOCKTON, LAURA LYNNE | — |
| 18556260 | COMPOUNDS | OTTON, ALICIA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18849834 | 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | STOCKTON, LAURA LYNNE | — |
| 18699825 | TRICYCLIC GPR65 MODULATORS | KENYON, JOHN S | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1625 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18849834 | 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | STOCKTON, LAURA LYNNE | 1626 | §102§112 | Non-Final OA | — | Pending | Sep 23, 2024 |
| 18699825 | TRICYCLIC GPR65 MODULATORS | KENYON, JOHN S | 1625 | §112DP | Non-Final OA | — | Pending | Apr 09, 2024 |
| 18556260 | COMPOUNDS | OTTON, ALICIA L | 1699 | §102§112 | Non-Final OA | — | Pending | Oct 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPathios Therapeutics Limited has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Laura Lynne Stockton has the most, with 1 of Pathios Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
